What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Biomarker-Driven Clinical Trials: Personalized Medicine in 2026

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

A biomarker is a measurable characteristic — a genetic mutation, protein level, imaging finding, or physiological measurement — that predicts disease risk, prognosis, or response to treatment. Biomarker-driven clinical trials use these markers to select patients most likely to benefit, enrich trial populations, and personalize dosing. Understanding biomarkers is increasingly essential for patients navigating trial eligibility.

Types of Biomarkers in Clinical Trials

Predictive biomarkers identify patients who will respond to a specific treatment. The most prominent examples are oncology molecular targets: EGFR mutations (predict response to erlotinib), HER2 amplification (trastuzumab), ALK rearrangements (crizotinib), PD-L1 expression (pembrolizumab). Without the biomarker, these drugs may be ineffective.

Prognostic biomarkers predict disease course regardless of treatment — NT-proBNP in heart failure, PSA in prostate cancer, amyloid PET in Alzheimer's disease. Trials use these to stratify randomization and ensure balanced arms.

Pharmacodynamic biomarkers confirm that the drug is hitting its target — HbA1c reduction in diabetes trials, amyloid clearance on PET in Alzheimer's trials. These provide early evidence of biological activity before clinical endpoints emerge.

Safety biomarkers detect early signs of toxicity — liver enzyme elevation (ALT, AST) for hepatotoxicity, creatinine for nephrotoxicity, troponin for cardiotoxicity.

Liquid Biopsy and ctDNA

Circulating tumor DNA (ctDNA) — fragments of cancer DNA shed into the bloodstream — can be detected by sensitive blood tests (liquid biopsy). ctDNA is used in oncology trials to: assess molecular response to treatment, detect minimal residual disease after surgery, identify resistance mutations when treatment fails, and screen for cancer recurrence.

Multiple trials now use ctDNA clearance as an early efficacy endpoint or to guide treatment intensification. The DYNAMIC trials (colorectal cancer) demonstrated that ctDNA-guided decisions could spare low-risk patients from unnecessary chemotherapy while identifying high-risk patients needing treatment escalation.

Genetic Biomarkers You May Encounter

BRCA1/2: Breast, ovarian, pancreatic, prostate cancer — required for PARP inhibitor trials
MSI-H/dMMR: Mismatch repair deficiency — predicts response to pembrolizumab across tumor types
APOE4: Alzheimer's risk — required for anti-amyloid trial stratification; affects ARIA risk assessment
KRAS/NRAS: Colorectal cancer — determines eligibility for EGFR antibody therapies
TMB (tumor mutational burden): High TMB predicts immunotherapy response across cancer types

Getting Your Biomarker Testing Done

Comprehensive genomic profiling (CGP) tests — such as Foundation One CDx, Tempus xT, or Guardant360 — can identify dozens of relevant biomarkers from a single tumor sample or blood draw. Many trials require or reimburse this testing as part of the screening process.

If you have a serious diagnosis and are interested in trial eligibility, ask your oncologist about CGP testing early in your treatment journey. Biomarker results can take 2–4 weeks and may determine which trials you qualify for — having results available accelerates the matching process.